TXA group (n = XXX) | Standard care group (n = XXX) | |
---|---|---|
Age, yr, mean (SD) | NN.N (NN.N) | NN.N (NN.N) |
Female sex, n (%) | NNN (X) | NNN (X) |
WFNS grade | ||
I, n (%) | N (X) | N (X) |
II, n (%) | N (X) | N (X) |
III, n (%) | N (X) | N (X) |
IV, n (%) | N (X) | N (X) |
V, n (%) | N (X) | N (X) |
Fisher grade | ||
II, n (%) | N (X) | N (X) |
III, n (%) | N (X) | N (X) |
IV, n (%) | N (X) | N (X) |
Medication prior to SAH | ||
Platelet inhibitor, n (%) | N (X) | N (X) |
Anticoagulation, n (%) | N (X) | N (X) |
Antihypertensive, n (%) | N (X) | N (X) |
None, n (%) | N (X) | N (X) |
Location of aneurysm | ||
Anterior circulation, n (%) | N (X) | N (X) |
Posterior circulation, n (%) | N (X) | N (X) |
None, n (%) | N (X) | N (X) |
Treatment modality | ||
Endovascular, n (%) | N (X) | N (X) |
Clipping, n (%) | N (X) | N (X) |
None, n (%) | N (X) | N (X) |